Itzykson, Raphael <br/><br/>
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.  [electronic resource] 

 -  Blood  Jan 2011 
 - 403-11 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1528-0020 
<br/><br/><label>Standard No.: </label>10.1182/blood-2010-06-289280  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antimetabolites, Antineoplastic--therapeutic use<br/>Azacitidine--therapeutic use<br/>Female<br/>Humans<br/>Kaplan-Meier Estimate<br/>Male<br/>Middle Aged<br/>Myelodysplastic Syndromes--drug therapy<br/>Prognosis<br/>Young Adult